Ma Yinglong: Subsidiary obtains Drug Registration Certificate for Nitric Oxide Drops in eye, Hydrochloride

Ma Yinglong announced that its subsidiary Jiangxi Ma Yinglong Meikang Pharmaceutical Co., Ltd. recently received the Drug Registration Certificate of Naphazoline Hydrochloride Eye Drops issued by the National Medical Products Administration, with a concentration of 0.05% and classified as a Class A non-prescription drug. The approval number is valid until July 7, 2031. This medication is used to treat itching symptoms caused by allergic conjunctivitis, with domestic sales reaching 154 million yuan in 2025 and the company having invested a total of 7.6621 million yuan in research and development. Approval of this drug helps to enrich the company's ophthalmic product line, but there are uncertainties in production and sales.